angiotensin ii
angiotensin ii: 5 clinical trials tracked.
angiotensin ii evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about angiotensin ii, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
An Open-Label, Single-Center Study of Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension Despite Receiving Fluid Therapy and Vasoactive Therapy
Primary endpoint: Percentage of patients who have improvement in mean arterial pressure or reduction in sum norepinephrine equivalent at Hour 2 after the start of Synthetic Angiotensin-II
Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)
Primary endpoint: Incidence of postoperative acute kidney injury, atrial fibrillation
DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) Pilot: Serum Biomarkers to Predict Response to Angiotensin II vs. Standard-of-care Vasopressor Therapy in the Treatment of Septic Shock, a Randomized Controlled Pilot Trial
Primary endpoint: Ability of baseline renin to predict norepinephrine equivalent dose (NED) at 3 hours
Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial
Primary endpoint: Total dose of norepinephrine (NE), averaged over case duration and total body weight, utilized during liver transplantation (LT) to maintain mean arterial pressure (MAP) greater than or equal to 65 mmHg.
Angiotensin II as a First-line Vasopressor for Distributive Shock During or After Heart Transplantation or Durable Left Ventricular Assist Device Implantation: A Pilot Study
Primary endpoint: Total Catecholamine Dose